Twelve-Week Hormone Pretreatment Improves IVF Outcomes

By Re Kayla 06/11/2026 3 min read 9 views

Gloved hand holding a petri dish containing bacterial colonies for scientific research. Photo: Edward Jenner/Pexels

Research published in BMC Pregnancy and Childbirth examines how an extended course of growth hormone (GH) before in-vitro fertilisation (IVF) influences embryo quality in women who have previously experienced IVF failures. The investigators evaluated a cohort of 192 participants younger than 38 years, each of whom had produced poor-quality embryos in earlier treatment cycles.

Participants were allocated into three distinct arms: one received no GH pretreatment, a second group underwent a short-term regimen lasting between two and four weeks, and a third group was given a prolonged schedule of twelve weeks. The primary outcomes measured included the proportion of good-quality embryos observed on day 3, the rate of blastocyst formation, and the ultimate live-birth results.

Study Findings

The analysis revealed that women who completed the twelve-week GH schedule generated a markedly higher share of good-quality embryos—46% of their embryos met the quality criteria—compared with 26% in the untreated cohort and 31% among those given the brief protocol. This advantage persisted after the researchers adjusted for differences in ovarian stimulation methods and baseline characteristics.

Growth hormone is believed to act through the GH/IGF-1 pathway, promoting follicular growth, supporting oocyte maturation, and mitigating oxidative stress within the ovarian environment. Because a follicle requires roughly 85 days to progress from its earliest stage to a mature state, a longer exposure to the hormone may better align with the natural timeline of folliculogenesis.

Real-World Cohort Study Details

Could a simple change in pretreatment duration improve outcomes for women with low-quality embryos? Clinicians often describe the problem as a puzzle with missing pieces. The research explores whether extending growth hormone (GH) pretreatment can help unlock better outcomes for this challenging population, offering evidence from a Chinese IVF center.

The authors stress that careful patient selection is required and that prospective research is needed before the approach can be adopted widely. Liu et al. report the findings in BMC Pregnancy and Childbirth, 2026, DOI 10.1186/s12884-026-09825-4.

Clinical Implications

When fresh embryo transfers were examined, the prolonged GH arm achieved a live-birth rate of 57%, a substantial increase over the untreated group, which remained at the earlier proportion. Cumulative live-birth figures across all transfers, however, did not differ in a statistically significant way among the three groups.

The authors caution that the study’s retrospective design, modest sample size, and specific selection criteria limit the ability to generalize the results to all IVF patients. They suggest that careful case selection will be essential before this approach can be recommended broadly.

For reproductive specialists, the data indicate that extending GH pretreatment could become a useful option for patients who continue to produce low-quality embryos despite having an adequate ovarian reserve. The findings show the relevance of follicular biology when customizing IVF protocols.

Because the evidence derives from a retrospective cohort, the investigators stress the need for prospective, randomised trials to confirm the benefit and to define the optimal timing and dosage of GH. The biological rationale aligns with the known duration of follicular development, supporting the plausibility of a longer regimen.

Ongoing research will determine whether this strategy can be integrated into standard IVF practice, potentially improving embryo development and increasing the chances of a successful pregnancy for this challenging patient population.